NASDAQ$PAHC
Phibro Animal Health Corporation · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Phibro Animal Health Corporation reported its financial results for the three months ended December 31, 2024, showing significant growth in net sales and net income.
Phibro Animal Health Corporation experienced substantial growth in the three months ended December 31, 2024, with net sales increasing by 24% to $309.3 million and net income rising by 50% to $3.185 million. This growth was largely driven by the acquisition of Zoetis's medicated feed additive portfolio and increased demand across its Animal Health segment.
- Net sales increased by 24% to $309.3 million for the three months ended December 31, 2024, compared to the same period last year.
- Net income grew by 50% to $3.185 million, up from $1.274 million in the prior year period.
- The Animal Health segment saw a 33% increase in net sales, primarily due to the acquisition of Zoetis's MFA portfolio.
- Gross profit improved by 30% to $101.9 million, with the gross margin increasing to 32.9% of net sales.
Headline financials
Revenue & EPS history
Phibro · Revenue · Quarterly
$309M
Revenue by segment
Phibro · $231M total across 3 segments · Q1 2024
- Animal Health$161M+3.6%69.4%
- Mineral Nutrition$56M-6.0%24.2%
- Performance Products$14.8M-17.8%6.4%
Forward guidance
The company's forward guidance is not explicitly stated in a consolidated section, but various factors influencing future performance are discussed, including ongoing conflicts, regulatory developments, and macroeconomic conditions.
Tailwinds
- Continued support for growth in the animal health industry due to global population growth and increased productivity.
- Expansion of medicated feed additives and water-soluble products categories through strategic acquisitions.
- Diversification of species and product offerings, complementing commercial operations and international infrastructure.
- Ability to meet supply commitments and maintain sufficient inventory despite regional tensions.
- Ongoing efforts to improve animal health and well-being through product development.
Headwinds
- Potential escalation of armed conflicts in Israel and Ukraine, leading to broader economic and security concerns.
- Possible disruption of operations, supply chain, and logistics due to conflicts and geopolitical instability.
- Uncertainty regarding the potential FDA withdrawal of approval for Mecadox® (carbadox) product, which could adversely affect financial results.
- Adverse macroeconomic developments, including tariffs and trade barriers, impacting the ability to sell products and services.
- Risks associated with changes in tax rates, heightened competition, and dependence on suppliers with regulatory approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
-0.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
56%
29 / 52 earnings
Positive
+22.0%
Q2 2026
Best reaction
-31.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -26.1% | -37.5% | -44.6% | |
| Q2 2026 | +22.0% | +26.2% | +16.9% | |
| Q1 2026 | +4.7% | +10.2% | -4.8% | |
| Q3 2025 | +14.7% | +26.9% | +24.2% | |
| Q2 2025 | +9.9% | +16.8% | +5.7% | |
| Q1 2025 | +2.8% | +11.8% | +1.6% | |
| Q4 2024 | +1.9% | -0.3% | +4.8% | |
| Q3 2024 | +5.5% | +8.0% | +2.3% | |
| Q2 2024 | +5.9% | +12.5% | +19.1% | |
| Q1 2024 | -18.9% | -19.3% | -8.4% | |
| Q4 2023 | -5.8% | -2.0% | -13.8% | |
| Q3 2023 | -8.4% | -8.0% | -12.0% | |
| Q2 2023 | -0.9% | -1.3% | -4.7% | |
| Q1 2023 | -5.5% | -8.0% | -14.2% | |
| Q4 2022 | -4.8% | -7.4% | -24.4% | |
| Q3 2022 | -4.0% | -2.9% | -0.5% | |
| Q2 2022 | +5.7% | +13.7% | +6.0% | |
| Q1 2022 | -0.8% | -0.3% | -10.1% | |
| Q4 2021 | -5.0% | -1.0% | -10.2% | |
| Q3 2021 | +8.1% | +3.9% | +14.7% | |
| Q2 2021 | +7.3% | +7.9% | +7.5% | |
| Q1 2021 | +4.5% | +8.1% | +10.0% | |
| Q4 2020 | +0.9% | +4.6% | -13.0% | |
| Q3 2020 | -4.6% | -4.8% | +15.7% | |
| Q2 2020 | +16.9% | +14.0% | +12.5% | |
| Q1 2020 | -8.1% | -4.8% | -0.0% | |
| Q4 2019 | -31.5% | -35.0% | -32.5% | |
| Q3 2019 | -19.7% | -17.2% | -17.0% | |
| Q2 2019 | -6.4% | -10.4% | -11.8% | |
| Q1 2019 | -8.7% | -12.5% | -22.1% | |
| Q4 2018 | -3.0% | -7.0% | -15.3% | |
| Q3 2018 | +4.2% | +3.2% | +9.7% | |
| Q2 2018 | +6.8% | +4.4% | +16.0% | |
| Q1 2018 | -4.9% | -8.2% | -12.9% | |
| Q4 2017 | -5.1% | -2.4% | -0.9% | |
| Q3 2017 | +6.0% | +10.9% | +18.4% | |
| Q2 2017 | +7.0% | +12.1% | +0.2% | |
| Q1 2017 | +11.3% | +8.9% | +3.4% | |
| Q4 2016 | +15.4% | +24.9% | +28.9% | |
| Q3 2016 | -10.3% | — | — | |
| Q2 2016 | -18.2% | — | — | |
| Q1 2016 | -3.4% | — | — | |
| Q4 2015 | -5.3% | — | — | |
| Q3 2015 | +7.9% | — | — | |
| Q2 2015 | +6.5% | — | — | |
| Q1 2014 | +5.5% | — | — | |
| Q1 2015 | +7.4% | — | — | |
| Q2 2014 | +0.3% | — | — | |
| Q4 2014 | +12.6% | — | — | |
| Q4 2013 | +1.0% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro